A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIVE PARALLEL GROUPS EFFICACY AND SAFETY STUDY OF NS 2330 (TESOFENSINE) (0.125 MG, 0.25 MG, 0.5 MG AND 1.0 MG) ADMINISTERED ORALLY ONCE DAILY OVER 14 WEEKS IN LEVODOPA TREATED PARKINSON PATIENTS WITH MOTOR FLUCTUATIONS: